Journal of Translational Medicine,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Jan. 30, 2025
Transarterial
chemoembolization
(TACE)
is
the
first-line
therapeutic
option
for
patients
with
intermediate-stage
hepatocellular
carcinoma
(HCC).
Tumor
neovascularization
allows
tumor
growth
and
may
facilitate
release
of
circulating
cells
(CTCs)
to
bloodstream
after
TACE.
We
investigated
relationship
between
early
CTCs
radiological
response
Prospective,
single-center
study
including
HCC
undergoing
a
first
TACE
from
January
2019
June
2023.
The
IsoFlux®
system
was
used
evaluate
EpCAM+
CTC
counts
before
TACE,
at
day
1
(D1),
30
Radiological
assessed
according
mRECIST
criteria
one
month
procedure.
vascularity
by
an
interventional
radiologist.
In
all,
48
were
included
(age
64.2
±
7.6
years,
14.6%
women).
levels
increased
D1
(114.0%
[IQR
76.5%-178.0%],
p
=
0.019)
normalized
baseline
in
(76.5%
41.3%-131.8%],
0.263).
Higher
(p
0.009)
0.026)
associated
hypervascularity.
Larger
size
[OR:
1.9
(95%
CI:
1.1–3.3),
0.020]
increase
5.3
1.3–21.0),
0.017]
independent
predictors
non-response
especially
those
hypervascular
lesions.
A
meaningful
24
h
suboptimal
Future
studies
should
role
dynamics
select
candidates
adjuvant
therapy
analyze
their
impact
on
long-term
outcomes.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(16), P. 2882 - 2882
Published: Aug. 19, 2024
Lung
cancer,
including
both
non-small
cell
lung
cancer
and
small
remains
the
leading
cause
of
cancer-related
mortality
worldwide,
representing
18%
total
deaths
in
2020.
Many
patients
are
identified
already
at
an
advanced
stage
with
metastatic
disease
have
a
worsening
prognosis.
Recent
advances
genetic
understanding
opened
new
avenues
for
personalized
treatments
targeted
therapies.
This
review
examines
latest
discoveries
genetics
discusses
key
biomarkers,
analyzes
current
clinical
therapies
based
on
this
information.
It
will
conclude
discussion
future
prospects
potential
research
directions.
Frontiers in Bioengineering and Biotechnology,
Journal Year:
2025,
Volume and Issue:
12
Published: Jan. 17, 2025
Cancer
continues
to
be
one
of
the
leading
causes
death
worldwide,
and
conventional
cancer
therapies
such
as
chemotherapy,
radiation
therapy,
surgery
have
limitations.
RNA
therapy
vaccines
hold
considerable
promise
an
alternative
for
their
ability
enable
personalized
with
improved
efficacy
reduced
side
effects.
The
principal
approach
is
induce
a
specific
immune
response
against
cells.
However,
major
challenge
in
immunotherapy
predict
which
patients
will
respond
treatment
monitor
vaccine
during
treatment.
Theragnostics,
integration
diagnostic
therapeutic
capabilities
into
single
hybrid
platform
system,
has
potential
address
these
challenges
by
enabling
real-time
monitoring
while
allowing
endogenously
controlled
adjustments.
In
this
article,
we
review
current
state-of-the-art
theragnostics
including
imaging
agents,
biomarkers,
other
tools
relevant
cancer,
application
development
personalization.
We
also
discuss
opportunities
further
clinical
translation
vaccines.
Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(2), P. 431 - 431
Published: Feb. 11, 2025
Background/Objectives:
The
PowerMag
system
(PM)
is
a
platform
for
the
isolation
of
circulating
tumor
cells
(CTCs)
by
depletion
CD45+-leukocytes.
However,
an
EpCAM−CD45−
cell
population
present
in
large
numbers
filtrates
collected
PM.
This
lowers
purity
CTCs
and
negatively
impacts
their
molecular
characterization.
aims
this
study
are
to
characterize
cellular
properties
upgrade
improve
CTC
purity.
Methods:
A
real-time
RT-PCR
assay,
Liu’s
stain
analysis,
Annexin
V
(AnxV)
binding
assay
were
used
define
cells.
An
upgraded
was
developed
remove
Clinical
blood
samples
evaluate
performance
system.
Results:
defined
as
apoptotic
cells,
which
displayed
body-like
morphology
elicited
AnxV
activity.
beads
in-house
can
effectively
bind
from
filtrates.
improved
generation
platform,
designated
PM
II,
integration
into
workflow
II
recovered
with
effective
removal
background
allowed
direct
profiling
cancer-related
gene
mutations
next-generation
sequencing
without
picking
further
purification.
Conclusions:
holds
great
promise
isolating
exploring
its
application
cancer
diagnosis
monitoring
clinical
setting.
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: April 3, 2025
Liquid
biopsies,
which
analyze
circulating
tumor
cells
or
cell-free
DNA
(ctDNA)
from
blood,
have
emerged
as
promising
cancer
detection
and
monitoring
tools.
Specifically,
human
papillomavirus
(HPV)
(cf)
is
gaining
recognition
a
prognostic
marker
in
high-risk
HPV-related
cancers.
However,
detecting
markers
for
cervical
(CC)
requires
highly
sensitive
techniques
to
quantify
HPV
DNA.
This
study
aimed
evaluate
the
use
of
droplet
digital
PCR
(ddPCR),
technique,
quantifying
patients,
both
at
baseline
(before
chemo-
radiotherapy)
during
follow-up,
assess
its
utility
marker.
Blood
samples
were
collected
60
patients
(Stages
I-IV)
AIIMS,
New
Delhi,
three
months
post-treatment.
Samples
10
healthy
controls
also
included.
Plasma
was
separated
stored
-
80
°C,
cfDNA
extracted
1
ml
plasma.
The
presence
types,
HPV16
HPV18,
35
assessed
using
ddPCR.
median
concentration
9.35
ng/µL
baseline,
decreased
7
after
treatment.
In
controls,
6.95
ng/µL.
ddPCR
screening
showed
that
rates
HPV18
45.71%
82.86%,
respectively.
A
significant
correlation
observed
between
cf
levels
size,
suggesting
potential
biomarker
disease
burden.
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: April 7, 2025
Circulating
tumor
cells
(CTCs)
are
cancerous
that
extravasate
from
the
primary
or
metastatic
foci
and
travel
through
bloodstream
to
distant
organs.
CTCs
provide
crucial
insights
into
cancer
metastasis,
evolution
of
genotypes
during
treatment,
development
chemo-
and/or
radio-resistance
disease
progression.
The
process
Epithelial-to-mesenchymal
transition
(EMT)
plays
a
key
role
in
formation,
as
this
enhances
cell's
migration
properties
is
often
associated
with
increased
invasiveness
thereby
leading
chemotherapy
resistance.
During
EMT
process,
lose
epithelial
markers
like
EpCAM
acquire
mesenchymal
such
vimentin
driven
by
transcription
factors
Snail
Twist.
typically
identified
using
specific
cell
surface
markers,
which
vary
depending
on
type.
Common
include
EpCAM,
used
for
cancers;
CD44
CD24,
stem
cells;
cytokeratins,
CK8
CK18.
Other
HER2/neu
can
also
be
target
types
stages.
Commonly,
immune-based
isolation
techniques
being
implemented
enrichment
CTCs.
This
review
emphasizes
clinical
relevance
CTCs,
particularly
understanding
drug
resistance
mechanisms,
underscores
importance
EMT-derived
multidrug
(MDR).
Moreover,
discusses
CTCs-specific
their
enrichment.
Ultimately,
EMT-specific
found
could
significant
information
halt
progression
enable
personalized
therapies.
